Here are the latest rating downgrades by Seeking Alpha analysts: Palantir (NASDAQ:PLTR). Buy to hold by Victor Dergunov.

DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins. Check out why I am lowering my rating on DXCM from buy to hold.

We recently published a list of 11 Best Medical Device Stocks to Buy Now. In this article, we are going to take a look at ...

Insulet beat first-quarter profit estimates on Thursday, buoyed by strong demand for its wearable insulin pumps, sending shares up 7% in extended trading.

Dexcom (NASDAQ:DXCM) announced today that it expanded its partnership with Oura, officially launching an integration with ...

After this recent quarterly performance and the resultant increase in stock price, an important question arises: is DXCM ...

DexCom's growth trend improved in 1Q25, but competition and shrinking market potential keep upside limited. Find out why DXCM ...

We recently published a list of These 10 Firms Soared Last Week, Here’s Why. In this article, we are going to take a look at ...

We recently published a list of What Propelled These 10 Firms’ Double-Digit Gains? In this article, we are going to take a ...

Short interest in DexCom Inc (NASDAQ:DXCM) decreased during the last reporting period, falling from 11.01M to 10.61M. This put 3.47% of the company's publicly available shares short. Short ...

Shares of DexCom Inc. DXCM surged 16.17% to $81.62 Friday, on what proved to be an all-around great trading session for the ...